查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924745

沙库巴曲Valsartan钠锭市场按产品类型、规格、剂型、分销管道和最终用户划分－2026年至2032年全球预测

Sacubitril Valsartan Sodium Tablets Market by Product Type, Strength, Dosage Form, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年沙库巴曲Valsartan钠锭市场价值为 102.2 亿美元，预计到 2026 年将成长至 109.8 亿美元，预计到 2032 年将达到 172.8 亿美元，复合年增长率为 7.78%。

主要市场统计数据
基准年 2025 102.2亿美元
预计年份：2026年 109.8亿美元
预测年份：2032年 172.8亿美元
复合年增长率 (%) 7.78%

简要概述沙库巴Valsartan钠锭，包括治疗背景、临床意义以及心血管护理相关人员的策略考量。

沙库巴曲Valsartan钠锭在现代心臟衰竭治疗中扮演关键角色。该药物结合了脑啡肽酶抑制剂和血管收缩素受体阻断剂，能够调节导致发病率和死亡率的疾病路径。临床医生越来越多地将这种联合治疗作为指南指导的医疗方案的一部分，用于治疗合适的患者群体。此疗法的应用取决于临床证据、药品目录决策和供应情况的综合考量。对于行业相关人员，了解临床应用趋势、治疗定位以及确保患者持续获得治疗的营运因素，对于制定协调一致的策略至关重要。

新兴的治疗方法、监管和供应趋势正在重塑沙库巴Valsartan锭市场格局，并影响其临床应用和分销网络。

沙库巴曲Valsartan钠锭的治疗和商业环境正经历多重融合的变革，这些变革正在重新定义产品的研发、分销和报销方式。真实世界证据产生和电子健康记录的进步，使得我们能够更清晰地了解患者在受控临床试验之外的治疗结果，从而影响药品目录的收录决策和医疗服务提供者的采纳。同时，多个司法管辖区的监管机构正在明确核准后风险管理和生产品质方面的要求，鼓励生产商优化其品质系统并提高供应链透明度。

评估2025年实施的关税变动对沙库巴Valsartan钠片供应链、价格压力和跨境贸易的累积影响

2025年的关税调整对包括沙库巴Valsartan钠片在内的药品国际供应链产生了复杂的下游影响。进口关税及相关行政变更正在影响原材料采购决策、製造地的经济效益以及成品供应商的相对竞争力。依赖跨境供应活性成分和成品製剂的製造商被迫重新评估合约条款、避险策略和库存缓衝，以确保临床通路的供应不间断。

透过细分市场获得更深入的洞察，揭示分销管道、最终用户、产品类型、剂型和剂量对产品可及性和临床应用的影响。

市场区隔有助于深入了解沙库巴Valsartan钠锭的使用管道和获取动态，而详尽的观点对于制定精准策略至关重要。检验分销管道揭示了营运现实的差异。医院药局在政府或私立医院的采购框架内运作，这些框架强调处方集委员会和机构合约。线上药局引入了直接面向患者的配送动态，但需要考虑监管合规性和低温运输。同时，零售药局既包括采用标准化采购的连锁药局，也包括依赖本地相关性和库存即时竞争的独立门市。

区域差异和商业性趋势（美洲、欧洲、中东和非洲、亚太地区）会影响製造、监管和分销策略。

地理差异会影响沙库巴Valsartan钠锭的监管合规、製造地选择和商业部署，而区域观点有助于确定产能投资的优先顺序。在美洲，整合的医疗体系、先进的支付模式和完善的分销网络为基于价值的合约和广泛的临床应用创造了机会，同时也要求严格的药物监测和与报销文件的协调一致。在欧洲、中东和非洲营运的相关人员面临着监管时间表、定价谈判框架和采购实践方面的差异，因此需要製定适应性强的打入市场策略和区域性的监管支持。

领先的开发商和製造商的企业定位和竞争策略将塑造该治疗领域的创新轨迹和伙伴关係机会。

该治疗领域的企业正透过差异化的研发投入、供应链建设和商业性合作策略来重塑竞争格局。一些企业强调整合式开发管道，将製剂改进与可靠的上市后证据结合，以保持临床优势。另一些企业则专注于生产规模和成本效益，以在价格竞争力方面取胜，或透过非专利上市和授权许可来扩大市场准入。药物研发企业与区域分销商和契约製造之间的策略合作，在加速产品进入市场和确保不同地域市场的稳定供应方面，仍然发挥着至关重要的作用。

为製造商、经销商和政策制定者提供切实可行的、优先排序的策略行动，以增强韧性、扩大患者获取途径并确保负责任的商业化。

行业领导者可以采取优先措施，增强韧性，扩大患者用药管道，并调整商业性策略以适应不断变化的临床和监管预期。首先，多元化采购管道并投资区域製造能力，可以降低关税波动和物流衝击带来的风险，同时缩短补货週期，并确保符合区域监管要求。其次，建立强大的真实世界证据项目，将治疗用途与有意义的临床结果联繫起来，有助于与支付方进行价值评估，并支持医疗机构将相关药物纳入药品目录。

对用于深入了解该治疗领域的多资讯来源调查方法、数据检验过程和分析方法进行透明的解释。

该分析基于透明、可重复的调查方法，整合了监管文件、临床文献、供应链资讯和相关人员访谈，从而形成一致的证据基础。资料检验方法包括交叉引用公开的监管文件和製造商资讯披露，以及透过与分销和采购专业人员的访谈来补充营运观察。跨多个资讯来源的三角验证降低了对任何单一资料集的依赖，并增强了对营运和策略洞察的信心。

策略要点综述，重点阐述与沙库巴曲Valsartan钠片剂使用相关的利害关係人的临床、商业和营运优先事项。

综合研究结果凸显了一系列策略重点，这些重点将临床证据、商业性执行和营运韧性联繫起来。在临床方面，与指南驱动的治疗方案保持一致，并为製剂研发人员提供可靠的真实世界疗效数据，对于确保药物在医院和门诊护理环境中的持续应用至关重要。在商业方面，将数位化药局解决方案与传统医院和零售通路结合的多元化分销模式，将有助于保障医疗服务的连续性，并满足不断变化的患者偏好。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 沙库巴曲Valsartan钠锭市场依产品类型划分

  • 品牌
  • 非专利的

9. 沙库巴曲Valsartan钠片市场（依规格划分）

  • 24/26mg
  • 49/51mg
  • 97/103mg

第十章 沙库巴曲Valsartan钠锭市场依剂型划分

  • 薄膜衣片
  • 药片

第十一章 沙库巴曲Valsartan钠片市场（依通路划分）

  • 离线
  • 在线的

第十二章 沙库巴曲Valsartan钠片市场（依最终用户划分）

  • 诊所
  • 居家照护
  • 医院

第十三章 沙库巴曲Valsartan钠锭市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 沙库巴曲Valsartan钠片市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国沙库巴曲Valsartan钠锭市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国沙库巴曲Valsartan钠片市场

第十七章：中国沙库巴曲Valsartan钠片市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Lupin Limited
  • MacLeod's Pharmaceuticals Ltd.
  • MSN Laboratories Private Limited
  • Mylan NV
  • Natco Pharma Limited
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C470

The Sacubitril Valsartan Sodium Tablets Market was valued at USD 10.22 billion in 2025 and is projected to grow to USD 10.98 billion in 2026, with a CAGR of 7.78%, reaching USD 17.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.22 billion
Estimated Year [2026] USD 10.98 billion
Forecast Year [2032] USD 17.28 billion
CAGR (%) 7.78%

A concise orientation to sacubitril valsartan sodium tablets, therapeutic context, clinical relevance, and strategic considerations for stakeholders in cardiovascular care

Sacubitril valsartan sodium tablets occupy a pivotal role within contemporary heart failure management, combining neprilysin inhibition and angiotensin receptor blockade to modify disease pathways that contribute to morbidity and mortality. Clinicians increasingly rely on this combination therapy as part of guideline-directed medical care for appropriate patient populations, and its adoption sits at the intersection of clinical evidence, formulary decisions, and supply availability. For industry stakeholders, understanding clinical adoption trends, therapeutic positioning, and the operational factors that enable consistent patient access is essential for coherent strategy development.

This introduction situates the compound within therapeutic and commercial contexts without reiterating clinical trial minutiae. It emphasizes practical implications for manufacturing, regulatory affairs, distribution logistics, and payer engagement. By framing the therapy as both a clinical asset and an operational challenge, the narrative sets expectations for the subsequent sections, which explore transformative shifts in the landscape, tariff-driven supply impacts, segmentation nuances, regional dynamics, competitive positioning, and recommended strategic actions. Readers will find a balanced synthesis that aligns clinical utility with the real-world considerations that determine whether patients receive timely and sustained access to treatment.

Emerging therapeutic, regulatory, and supply dynamics reshaping the sacubitril valsartan sodium tablet landscape and influencing clinical adoption and distribution networks

The therapeutic and commercial environment for sacubitril valsartan sodium tablets is undergoing several converging shifts that are redefining how the product is developed, distributed, and reimbursed. Advances in real-world evidence generation and electronic health records are enabling clearer illustrations of patient outcomes outside controlled trials, thereby influencing formulary decisions and provider uptake. Simultaneously, regulators in multiple jurisdictions are clarifying post-approval requirements for risk management and manufacturing quality, prompting manufacturers to optimize quality systems and supply chain transparency.

Moreover, digital distribution channels and growing patient preference for pharmacy home delivery are altering traditional dispensing patterns and placing new demands on cold-chain integrity and adherence support. Payers and integrated delivery networks are placing greater emphasis on value-based contracting and outcomes-linked arrangements, which encourages manufacturers to demonstrate clear linkage between therapeutic use and measurable clinical endpoints. Taken together, these dynamics are prompting stakeholders to re-evaluate commercialization strategies, invest in strengthened real-world data programs, and pursue more collaborative relationships with health systems to ensure both clinical uptake and operational resilience.

Assessment of the cumulative implications of United States tariff changes in 2025 on supply chains, pricing pressures, and cross-border trade of sacubitril valsartan sodium tablets

Recent tariff adjustments enacted in 2025 have created complex downstream effects for the international supply chains that support pharmaceutical products, including sacubitril valsartan sodium tablets. Import duties and related administrative changes affect input sourcing decisions, manufacturing location economics, and the relative competitiveness of finished product suppliers. Manufacturers that relied on cross-border supply of active pharmaceutical ingredients or finished dosage forms have had to reassess contract terms, hedging strategies, and inventory buffers to maintain uninterrupted supply to clinical channels.

Consequently, procurement teams have increased emphasis on supplier diversification and nearshoring options to reduce exposure to tariff volatility and logistical friction. Distributors and wholesalers face altered landed-cost calculations that may necessitate contract re-pricing and renegotiation with institutional customers, while hospital systems adjust procurement timing to mitigate cost spikes. In parallel, manufacturers are evaluating strategic inventory placement and alternative trade routes to preserve distribution continuity. These collective actions illustrate how tariff shifts propagate through manufacturing, logistics, and commercial negotiations, compelling stakeholders to adopt flexible sourcing models, reinforce contract agility, and embed tariff scenario planning within broader risk management frameworks.

Deep segmentation-driven insights revealing how distribution channels, end-users, product types, strengths, and dosage forms influence access and clinical utilization

Segmentation drives a nuanced understanding of utilization pathways and access dynamics for sacubitril valsartan sodium tablets, and a granular view is essential for targeted strategy. Examining distribution channels reveals divergent operational realities: hospital pharmacies operate within government or private hospital purchasing frameworks that emphasize formulary committees and institutional contracts, online pharmacies introduce direct-to-patient fulfillment dynamics with regulatory compliance and cold-chain considerations, and retail pharmacies manifest as chain-based operations with standardized procurement alongside independent outlets that compete on local relationships and immediacy of stock.

End-user segmentation further clarifies demand signals by distinguishing clinic settings from home care delivery and hospital-based administration, each of which imposes specific requirements for packaging, patient support, and adherence monitoring. Product-type differentiation between branded and generic versions affects pricing structures, intellectual property considerations, and commercial messaging, while strength variations-24/26 mg, 49/51 mg, and 97/103 mg-demand manufacturing flexibility and inventory planning to meet prescriber preference and titration protocols. Dosage form distinctions such as film-coated tablets versus standard tablets introduce manufacturing process choices and influence patient acceptability and shelf stability. Together, these segmentation dimensions inform channel strategies, production prioritization, and patient engagement approaches that align clinical practice patterns with supply-side execution.

Regional differentiation and commercial dynamics across Americas, Europe Middle East & Africa, and Asia-Pacific informing manufacturing, regulatory, and distribution strategies

Geographic nuances shape regulatory interactions, manufacturing location decisions, and commercial deployment for sacubitril valsartan sodium tablets, and a regional lens helps prioritize capability investments. In the Americas, integrated health systems, advanced payer models, and established distribution networks create opportunities for value-based contracting and broad clinical adoption, yet they also require alignment with stringent pharmacovigilance and reimbursement documentation. Stakeholders operating in Europe, Middle East & Africa confront heterogeneity in regulatory timelines, pricing negotiation frameworks, and procurement practices, which favors adaptive market entry strategies and localized regulatory support.

Across Asia-Pacific, rapid growth in health infrastructure, an expanding base of chronic disease management programs, and active pharmaceutical manufacturing capacity present both demand potential and opportunities for regional production. However, this region also features diverse regulatory expectations and variable patient affordability dynamics that necessitate tiered commercialization approaches. In all regions, stakeholders must balance global quality standards with localized operational execution, leveraging strategic partnerships and regulatory intelligence to accelerate approvals, maintain supply continuity, and optimize distribution networks for timely patient access.

Corporate positioning and competitive behaviors of leading developers and manufacturers shaping innovation trajectories and partnership opportunities in this therapeutic class

Companies participating in this therapeutic category exhibit differentiated approaches to research investment, supply chain architecture, and commercial partnerships, shaping the competitive landscape. Some firms emphasize integrated development pathways that couple formulation enhancements with robust post-market evidence generation to sustain clinical preference. Others concentrate on manufacturing scale and cost efficiency to compete on affordability and broaden access through generic introductions or licensing arrangements. Strategic alliances between originators and regional distributors or contract manufacturers continue to be central to accelerating market entry and ensuring consistent supply in geographically diverse markets.

In addition, corporate behavior reflects varying prioritization of differentiated services such as patient support programs, digital adherence solutions, and outcome measurement platforms. These ancillary offerings increasingly influence prescriber choice and payer negotiations by demonstrating treatment value beyond clinical endpoints. Observing competitor movements in intellectual property management, global production footprints, and commercial partnerships provides actionable signals for entities seeking to position their portfolio advantageously, whether through innovation-led differentiation, cost-focused scalability, or collaborative distribution models that extend reach while protecting operational resilience.

Practical, prioritized strategic actions for manufacturers, distributors, and policymakers to enhance resilience, patient access, and responsible commercialization

Industry leaders can implement prioritized actions that strengthen resilience, expand patient access, and align commercial approaches with evolving clinical and regulatory expectations. First, investing in diversified sourcing and regional manufacturing capacity reduces exposure to tariff disruptions and logistics shocks, while concurrently shortening replenishment cycles and supporting localized regulatory compliance. Second, building robust real-world evidence programs that link therapeutic use to meaningful clinical outcomes enables value-based discussions with payers and supports formulary inclusion across institutional settings.

Third, enhancing distribution strategies to incorporate digital pharmacy channels, direct-to-patient delivery, and strengthened hospital pharmacy integration will improve adherence and reduce interruptions in therapy. Fourth, adopting flexible pricing strategies and risk-sharing arrangements can expedite access while aligning incentives across payers, providers, and manufacturers. Finally, expanding patient support services and digital adherence tools complements clinical therapy by addressing persistence and tolerability concerns. Executing these recommendations requires cross-functional alignment between R&D, manufacturing, commercial, and regulatory teams, with leadership commitment to measurable milestones and continuous improvement based on stakeholder feedback.

Transparent explanation of multi-source research methodology, data validation practices, and analytic approaches used to produce robust insights on this therapy class

The analysis draws on a transparent and reproducible methodology that synthesizes regulatory documents, clinical literature, supply chain intelligence, and stakeholder interviews to form a coherent evidence base. Data validation practices included cross-referencing public regulatory filings with manufacturer disclosures and corroborating operational observations through interviews with distribution and procurement professionals. Triangulation across sources reduced reliance on any single dataset and enhanced confidence in operational and strategic findings.

Analytic approaches combined qualitative synthesis with scenario-based supply chain stress testing and comparative review of regulatory frameworks across major regions. The methodology emphasized traceability of conclusions to source material, rigorous review cycles, and subject matter expert validation to ensure that insights reflected both documented facts and practical realities encountered by health systems and commercial partners. Where appropriate, sensitivity analyses examined alternative operational responses to tariff and supply disruptions, enabling readers to appreciate plausible strategic pathways and the prerequisites for successful implementation.

Synthesis of strategic takeaways emphasizing clinical, commercial, and operational priorities for stakeholders engaged with sacubitril valsartan sodium tablet utilization

The synthesis of findings underscores a set of strategic priorities that bridge clinical evidence, commercial execution, and operational resilience. Clinically, maintaining alignment with guideline-directed therapy and ensuring prescribers have access to robust real-world outcomes data will be decisive in securing sustained utilization within hospital and ambulatory settings. Commercially, diversified distribution approaches that integrate digital pharmacy solutions with traditional hospital and retail pathways support continuity of care and meet evolving patient preferences.

Operational priorities include strategic sourcing and inventory practices to mitigate tariff and logistics volatility, as well as investment in manufacturing flexibility to accommodate strength and dosage-form variations. Corporate strategies that pair differentiated clinical services with cost-efficient production models will be best positioned to navigate payer scrutiny and institutional contracting. In summary, stakeholders that proactively integrate evidence generation, supply chain resilience, and patient-centered distribution mechanisms will optimize both clinical impact and commercial performance in a dynamic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sacubitril Valsartan Sodium Tablets Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Sacubitril Valsartan Sodium Tablets Market, by Strength

  • 9.1. 24/26 mg
  • 9.2. 49/51 mg
  • 9.3. 97/103 mg

10. Sacubitril Valsartan Sodium Tablets Market, by Dosage Form

  • 10.1. Film-Coated Tablet
  • 10.2. Tablet

11. Sacubitril Valsartan Sodium Tablets Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Sacubitril Valsartan Sodium Tablets Market, by End-User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Sacubitril Valsartan Sodium Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sacubitril Valsartan Sodium Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sacubitril Valsartan Sodium Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Sacubitril Valsartan Sodium Tablets Market

17. China Sacubitril Valsartan Sodium Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aspen Pharmacare Holdings Limited
  • 18.6. Aurobindo Pharma Limited
  • 18.7. Cipla Limited
  • 18.8. Dr. Reddy's Laboratories Ltd.
  • 18.9. Glenmark Pharmaceuticals Ltd.
  • 18.10. Hetero Labs Limited
  • 18.11. Lupin Limited
  • 18.12. MacLeod's Pharmaceuticals Ltd.
  • 18.13. MSN Laboratories Private Limited
  • 18.14. Mylan N.V.
  • 18.15. Natco Pharma Limited
  • 18.16. Novartis AG
  • 18.17. Orion Corporation
  • 18.18. Pfizer Inc.
  • 18.19. Sandoz International GmbH
  • 18.20. Sun Pharmaceutical Industries Ltd.
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Torrent Pharmaceuticals Ltd.
  • 18.23. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 24/26 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 24/26 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 24/26 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 49/51 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 49/51 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 49/51 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 97/103 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 97/103 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 97/103 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY FILM-COATED TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY FILM-COATED TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY FILM-COATED TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 103. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 121. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 127. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)